PHASE III, RANDOM, DB, PLACEBO, MULTICTR, SUBCU INSULIN & RHIGF-1 FOR IDDM

III 期、随机、DB、安慰剂、MULTICTR、SUBCU 胰岛素

• 批准号: 6281839
• 负责人: KATHRYN M THRAILKILL
• 金额: $ 3.06万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281839
• 关键词: clinical research; combination chemotherapy; diabetes mellitus therapy; drug administration routes; hormone therapy; human subject; human therapy evaluation; insulin; insulinlike growth factor; recombinant proteins

To evaluate the safety and efficacy of subcutaneous recombinant human Insulin-like Growth Factor-I (rhIGF-2), administered twice daily, as co- therapy with insulin, in patients with Type I diabetes mellitus. The effects of rhIGF-1 therapy on glycemic control will be compared with conventional diabetic therapy using insulin alone.

评价重组人胰岛素皮下注射的安全性和有效性 胰岛素样生长因子-I（rhIGF-2），每日两次给药， 1型糖尿病患者的胰岛素治疗。 的 rhIGF-1治疗对血糖控制的效果将与 传统的糖尿病治疗仅使用胰岛素。